The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture: (VITAMINA_D)
Primary Purpose
Hip Fracture, Vitamin D Deficiency
Status
Completed
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Calcifediol (Vitamin D)
Sponsored by
About this trial
This is an interventional treatment trial for Hip Fracture focused on measuring hip fracture, elderly, vitamin D, rehabilitation
Eligibility Criteria
Inclusion Criteria: Patients aged 75 years or over with fragility hip fracture (requiring surgical treatment) and vitamin D deficiency; able to provide informed consent, either directly or via the person responsible.
Definitions:
- Fragility hip fracture: understood as such those that are produced by trauma of low intensity (for example, falls from the own height in standing or smaller)
- Vitamin D deficiency: 25OHD serum levels < 30 ng / mL
Exclusion Criteria:
- Presence of severe functional dependence prior to fracture of the femur (Barthel Index < 35 points)
- Diagnosis of dementia to a moderate degree (defined on "Global Deterioration Scale" (GDS) and "Functional Assessment Staging" (FAST), GDS-FAST > 5).
- Medical conditions that contraindicate receiving vitamin D supplementation: hypercalcemia (calcemia> 10.5 mg / dL), hyperparathyroidism; chronic renal failure with glomerular filtration rate (GFR) <30 mL / min, calcium lithiasis; pathologies with risk of hypercalcemia (tuberculosis, sarcoidosis ...), as well as pathologies involving intestinal malabsorption.
- Hypersensitivity to the active substance or to any of the excipients.
- Use of drugs that interact with the use of vitamin D and with the risk of causing hypercalcemia (phenytoin, phenobarbital, primidone, digoxin).
- Reduced life expectancy (<12 months) due to the presence of advanced concomitant or end-of-life conditions.
Sites / Locations
- Consorci Sanitari de Terrassa
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Calcifediol (Vitamin D) loading-dose
Calcifediol (Vitamin D) at clinical practice dose
Arm Description
Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
Participants in the control group will receive 16.000 U / week for five weeks
Outcomes
Primary Outcome Measures
Functional gain
Defined as a 15-point improvement in the Barthel Index
Secondary Outcome Measures
Improvement serum Vitamin D (25OHD) levels
Defined as a vitamin D levels > 30 ng/mL
Improvement of muscle strength
Using handheld dynamometer to measure (kg)
Improvement of muscle mass
Using bioimpedance analysis to measure (kg)
Full Information
NCT ID
NCT03213886
First Posted
June 27, 2017
Last Updated
January 31, 2021
Sponsor
Leonor Cuadra Llopart
Collaborators
Fundacio Salut i Envelliment UAB
1. Study Identification
Unique Protocol Identification Number
NCT03213886
Brief Title
The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture:
Acronym
VITAMINA_D
Official Title
A Prospective Randomized Trial Comparing the Effects of 2 Vitamin D Supplementation Regimens in Elderly People After Hip Fracture Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
April 20, 2019 (Actual)
Study Completion Date
July 30, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Leonor Cuadra Llopart
Collaborators
Fundacio Salut i Envelliment UAB
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will be done to evaluate the effect of load dose of vitamin D compared to the dose of usual clinical practice, in improving mobility and reducing disability in older people following a hip fracture.
Detailed Description
Hip fractures and related disabilities are important public health issues for elderly people around the world. Attending the progressive aging of the population, an increase in the number of hip fractures is expected. In fact, some studies estimate that, globally, the incidence will exceed 6 million in 2050. In Spain, approximately 33,000 hip fracture occur annually, with an overall incidence of 517 cases per 100,000 elderly people. 90% occur in people over 64 years of age and the incidence increases exponentially beyond 80 years (> 64: 97/100000 inhabitants-year;> 85: 1898/100000 inhabitants-year).
Regarding the functional prognosis, those patients who survive the episode of the fracture often suffer a functional impairment. Outcomes for people who survive hip fracture are of concern, with more than one-quarter dying within a two-year period, and most of them not recovering their previous functional level. More than 10 % of survivors will be unable to return to their previous residence.
Vitamin D deficiency (serum 25 hydroxyvitamin D, 25OHD, level < 30 ng/mL) is commonly associated with hip fracture in elderly people. Without preventive treatment, however, vitamin D deficiency following hip fracture may result in proximal muscle weakness, pain, reduced dynamic balance and performance speed.
It is not clear how much Vitamin D must be taken in order to reach the optimal level. Although the benefits of supplementing patients with at least 800 to 1000 units (U)/day Vitamin D3 may be recognized, there is little information available to guide physicians regarding the appropriate management of hip fracture patients who may be severely Vitamin D deficient, specially in acute hip fracture patients.
A randomized controlled trial, including 50 older adults (aged 75 or over) who having suffered a hip fracture and with vitamin D deficiency, will be carried out. After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group. For the intervention group, participants will receive 16.000 U Calcifediol oral daily along 5 days. For the control group will receive 16.000 U Calcifediol oral weekly along 5 weeks.
Functional status will be evaluated using Barthel Index, as well the proportion of patients reaching an optimal level of 25OHD (> 30 ng/mL) will be determined at discharge from hospital (1 month approximately), 3, 6 and 12 months of follow up.
Secondary measures include the Timed Up and Go test, gait speed test, Short Physical Performance Battery to compare the effect of the Vitamin D supplementation strategies on functional and muscle strength scales. In addition, to measure the strength and muscle mass will be used handheld dynamometer and bioimpedance analysis respectively
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Fracture, Vitamin D Deficiency
Keywords
hip fracture, elderly, vitamin D, rehabilitation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Calcifediol (Vitamin D) loading-dose
Arm Type
Experimental
Arm Description
Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
Arm Title
Calcifediol (Vitamin D) at clinical practice dose
Arm Type
Active Comparator
Arm Description
Participants in the control group will receive 16.000 U / week for five weeks
Intervention Type
Drug
Intervention Name(s)
Calcifediol (Vitamin D)
Intervention Description
After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group.
For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.
For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.
Both groups:
Will follow the usual hip fracture rehabilitation pathway.
25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)
Primary Outcome Measure Information:
Title
Functional gain
Description
Defined as a 15-point improvement in the Barthel Index
Time Frame
at 6 months of follow up
Secondary Outcome Measure Information:
Title
Improvement serum Vitamin D (25OHD) levels
Description
Defined as a vitamin D levels > 30 ng/mL
Time Frame
at baseline, 1, 3, 6 and 12 months of follow-up.
Title
Improvement of muscle strength
Description
Using handheld dynamometer to measure (kg)
Time Frame
at 3, 6 and 12 months of follow up.
Title
Improvement of muscle mass
Description
Using bioimpedance analysis to measure (kg)
Time Frame
at 3, 6 and 12 months of follow up.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 75 years or over with fragility hip fracture (requiring surgical treatment) and vitamin D deficiency; able to provide informed consent, either directly or via the person responsible.
Definitions:
Fragility hip fracture: understood as such those that are produced by trauma of low intensity (for example, falls from the own height in standing or smaller)
Vitamin D deficiency: 25OHD serum levels < 30 ng / mL
Exclusion Criteria:
Presence of severe functional dependence prior to fracture of the femur (Barthel Index < 35 points)
Diagnosis of dementia to a moderate degree (defined on "Global Deterioration Scale" (GDS) and "Functional Assessment Staging" (FAST), GDS-FAST > 5).
Medical conditions that contraindicate receiving vitamin D supplementation: hypercalcemia (calcemia> 10.5 mg / dL), hyperparathyroidism; chronic renal failure with glomerular filtration rate (GFR) <30 mL / min, calcium lithiasis; pathologies with risk of hypercalcemia (tuberculosis, sarcoidosis ...), as well as pathologies involving intestinal malabsorption.
Hypersensitivity to the active substance or to any of the excipients.
Use of drugs that interact with the use of vitamin D and with the risk of causing hypercalcemia (phenytoin, phenobarbital, primidone, digoxin).
Reduced life expectancy (<12 months) due to the presence of advanced concomitant or end-of-life conditions.
Facility Information:
Facility Name
Consorci Sanitari de Terrassa
City
Terrassa
State/Province
Barcelona
ZIP/Postal Code
08227
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
28297132
Citation
Duque G, Daly RM, Sanders K, Kiel DP. Vitamin D, bones and muscle: myth versus reality. Australas J Ageing. 2017 Mar;36 Suppl 1:8-13. doi: 10.1111/ajag.12408.
Results Reference
background
PubMed Identifier
28382112
Citation
Hill TR, Aspray TJ. The role of vitamin D in maintaining bone health in older people. Ther Adv Musculoskelet Dis. 2017 Apr;9(4):89-95. doi: 10.1177/1759720X17692502. Epub 2017 Feb 14.
Results Reference
background
PubMed Identifier
28341251
Citation
Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017 Oct;173:313-316. doi: 10.1016/j.jsbmb.2017.03.018. Epub 2017 Mar 22.
Results Reference
background
PubMed Identifier
28346568
Citation
Laiz A, Malouf J, Marin A, Longobardi V, de Caso J, Farrerons J, Casademont J. Impact of 3-Monthly Vitamin D Supplementation Plus Exercise on Survival after Surgery for Osteoporotic Hip Fracture in Adult Patients over 50 Years: A Pragmatic Randomized, Partially Blinded, Controlled Trial. J Nutr Health Aging. 2017;21(4):413-420. doi: 10.1007/s12603-016-0773-3.
Results Reference
background
PubMed Identifier
27515154
Citation
Mak JC, Mason RS, Klein L, Cameron ID. An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial. BMC Musculoskelet Disord. 2016 Aug 11;17:336. doi: 10.1186/s12891-016-1174-9.
Results Reference
background
PubMed Identifier
26429406
Citation
Sprague S, Petrisor B, Scott T, Devji T, Phillips M, Spurr H, Bhandari M, Slobogean GP. What Is the Role of Vitamin D Supplementation in Acute Fracture Patients? A Systematic Review and Meta-Analysis of the Prevalence of Hypovitaminosis D and Supplementation Efficacy. J Orthop Trauma. 2016 Feb;30(2):53-63. doi: 10.1097/BOT.0000000000000455.
Results Reference
background
Learn more about this trial
The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture:
We'll reach out to this number within 24 hrs